AXL Is a Potential Target for the Treatment of Intestinal Fibrosis
- 16 February 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 27 (3), 303-316
- https://doi.org/10.1093/ibd/izaa169
Abstract
Fibrosis is the final common pathway to intestinal failure in Crohn’s disease, but no medical therapies exist to treat intestinal fibrosis. Activated myofibroblasts are key effector cells of fibrosis in multiple organ systems, including the intestine. AXL is a receptor tyrosine kinase that has been implicated in fibrogenic pathways involving myofibroblast activation. We aimed to investigate the AXL pathway as a potential target for the treatment of intestinal fibrosis. To establish proof of concept, we first analyzed AXL gene expression in 2 in vivo models of intestinal fibrosis and 3 in vitro models of intestinal fibrosis. We then tested whether pharmacological inhibition of AXL signaling could reduce fibrogenesis in 3 in vitro models of intestinal fibrosis. In vitro testing included 2 distinct cell culture models of intestinal fibrosis (matrix stiffness and TGF-β1 treatment) and a human intestinal organoid model using TGF-β1 cytokine stimulation. Our findings suggest that the AXL pathway is induced in models of intestinal fibrosis. We demonstrate that inhibition of AXL signaling with the small molecule inhibitor BGB324 abrogates both matrix-stiffness and transforming growth factor beta (TGF-β1)–induced fibrogenesis in human colonic myofibroblasts. AXL inhibition with BGB324 sensitizes myofibroblasts to apoptosis. Finally, AXL inhibition with BGB324 blocks TGF-β1-induced fibrogenic gene and protein expression in human intestinal organoids. The AXL pathway is active in multiple models of intestinal fibrosis. In vitro experiments suggest that inhibiting AXL signaling could represent a novel approach to antifibrotic therapy for intestinal fibrosis such as in Crohn’s disease.Keywords
Funding Information
- NIDDK (R01 DK 118154, T32 DK 094775)
This publication has 69 references indexed in Scilit:
- First Axl inhibitor enters clinical trialsNature Biotechnology, 2013
- Matrix Stiffness Corresponding to Strictured Bowel Induces a Fibrogenic Response in Human Colonic FibroblastsInflammatory Bowel Diseases, 2013
- Identification of Axl as a downstream effector of TGF-β1 during Langerhans cell differentiation and epidermal homeostasisThe Journal of Experimental Medicine, 2012
- Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: Impact of a “Top-Down” approach to intestinal fibrosis in miceInflammatory Bowel Diseases, 2012
- Prior Helicobacter pylori infection ameliorates Salmonella typhimurium-induced colitisInflammatory Bowel Diseases, 2011
- Themes in fibrosis and gastrointestinal inflammationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2011
- Directed differentiation of human pluripotent stem cells into intestinal tissue in vitroNature, 2010
- Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and AdultsGastroenterology, 2008
- Noninvasive Ultrasound Elasticity Imaging (UEI) of Crohn's Disease: Animal ModelJapanese Journal of Clinical Oncology, 2008
- Myofibroblast contraction activates latent TGF-β1 from the extracellular matrixThe Journal of cell biology, 2007